Morrison Foerster advised New Enterprise Associates, 4BIO Capital, and UPMC Enterprises as investors in Code Biotherapeutics’ $75 million Series A financing (Code Bio).
Code Biotherapeutics is a biotechnology company pioneering the development of genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA®, Code Bio’s approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases.
New Enterprise Associates, 4BIO Capital and UPMC Enterprises were joined by Northpond Ventures, which led the financing round, with additional participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures and Code Bio’s existing investors, CureDuchenne Ventures, the JDRF T1D Fund, and Takeda Ventures. The proceeds will enable Code Bio to advance its lead programs to treat and cure rare and prevalent genetic diseases, expand its pipeline and platform applications, and further scale manufacturing and operations.
MoFo previously represented New Enterprise Associates, 4BIO Capital and UPMC Enterprises in Code Bio’s $10 million Series Seed financing, which closed in March 2021.
The MoFo team advising the investors was led San Diego corporate associate Andrew Dixon, along with San Diego corporate associates Patrick Boyle and Brooke Maker and New York corporate partner Spencer Klein.